The licensing agreement between the two firms is consistent with Taconic's focus on providing easy access to genetically engineered models that help biopharmaceutical companies and academic researchers advance the speed and relevance of in vivo drug discovery studies. Taconic's C57BL/6NTac is widely used by organizations globally to generate and breed precisely defined genetically engineered models for non-clinical studies and translational research.
David T. Hansen, President of Taconic's Research Models and Services business unit comments on the importance of the new licensing agreement with InnoSer: "The licensing agreement between Taconic and InnoSer will be extremely valuable to researchers in the Netherlands. As the global leader in the generation, licensing, breeding and distribution of genetically engineered models, part of Taconic's mission is to make these resources easily available to researchers. Our licensing agreement with InnoSer will help us continue to achieve that objective and will reduce costs for researchers in the Netherlands."
InnoSer's facility in the Netherlands will begin receiving shipments immediately from Taconic to meet the growing demand for the B6 model. Jan Bartels, founder and Principal at InnoSer, believes having access to the B6 model will be particularly helpful to his firm's focus on delivering high quality models to academic research institutions. "One of the main reasons we established InnoSer was to help advance the work of academic researchers in basic research and drug development. Their efforts are very important to finding cures to many of the illnesses that affect the quality of life of people worldwide. Our clients need access to important models like Taconic's B6, given its broad application in basic research and drug discovery. We are very pleased that InnoSer will now be distributing that model to our client base and look forward to expanding our relationship with Taconic in the future."
Taconic and InnoSer will be attending the FELASA/SECAL Congress Meeting June 10-13 in Barcelona, Spain. Representatives from both firms will be available at the Taconic trade show booth (#154/155) to answer questions from research professionals about the licensing agreement and how to obtain Taconic's C57BL/6NTac model in the Netherlands from InnoSer.
Taconic is a global provider of genetically engineered mouse and rat models and services. As a full-service industry leader, founded in 1952, Taconic helps clients acquire, test, develop, breed, cryopreserve, prepare, and distribute highly relevant research lines worldwide. Headquartered in New York's Hudson River Valley, Taconic operates six breeding facilities and three service laboratories in the U.S. and Europe and maintains over 850 employees committed to technological innovation. Taconic's products and services are used by over 1250 companies and academic research institutions in nearly 50 nations worldwide.
InnoSer's core business is providing tailored services to investigators working with genetically altered (GA) research models under high quality and defined lab conditions. InnoSer was founded in 2011 to accommodate the increasing demand for professional services and infrastructure of academic and commercial research institutes in the Netherlands and other European countries. InnoSer offers services for in-vivo and in-vitro bio research which includes colony management, sanitation, cryopreservation, re-derivation, pathology and GEMM generation. All InnoSer's services are open to public and private enterprises as well as individual investigators.